Paynter, Nina P.

Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association

Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation

Cardiovascular Health and Risk FactorsHealthcare Systems and Public Health

Cited by 7,333

Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association

Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation

Cardiovascular Health and Risk FactorsHealthcare Systems and Public Health

Cited by 6,149

Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association

Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation

Cardiovascular Health and Risk FactorsHealthcare Systems and Public Health

Cited by 5,292

Executive Summary: Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association

Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation

Cardiovascular Health and Risk FactorsHealthcare Systems and Public Health

Cited by 1,512

Executive Summary: Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association

Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation

Cardiovascular Health and Risk FactorsHealthcare Systems and Public Health

Cited by 1,408

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine

Atherosclerosis and Cardiovascular DiseasesLipoproteins and Cardiovascular Health

Cited by 1,317

Executive Summary: Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association

Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation

Cardiovascular Health and Risk FactorsHealthcare Systems and Public Health

Cited by 1,294

C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men

Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M., & Cook, N. R. (2008) · Circulation

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 841

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 749

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal

Atherosclerosis and Cardiovascular DiseasesInflammatory Biomarkers in Disease Prognosis

Cited by 368

Association between a literature-based genetic risk score and cardiovascular events in women

Paynter, N. P. (2010) · JAMA

Genetic Associations and EpidemiologyNutrition, Genetics, and Disease

Cited by 361

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 319

Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study

Fox, C. S., Pencina, M. J., Wilson, P. W. F., Paynter, N. P., Vasan, R. S., & D’Agostino, R. B. (2008) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Function and Risk Factors

Cited by 247

Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption

Cornelis, M. C., Monda, K. L., Yu, K., Paynter, N., Azzato, E. M., Bennett, S. N., Berndt, S. I., Boerwinkle, E., Chanock, S., Chatterjee, N., et al. (2011) · PLoS Genetics

Coffee research and impactsGenetic Associations and Epidemiology

Cited by 228

Novel locus including FGF21 is associated with dietary macronutrient intake

Chu, A. Y., Workalemahu, T., Paynter, N. P., Rose, L. M., Giulianini, F., Tanaka, T., Ngwa, J. S., Qi, Q., Curhan, G. C., Rimm, E. B., et al. (2013) · Human Molecular Genetics

Nutrition, Genetics, and DiseaseGenetic Associations and Epidemiology

Cited by 195

Estimating treatment effects for individual patients based on the results of randomised clinical trials

Dorresteijn, J. A. N., Visseren, F. L. J., Ridker, P. M., Wassink, A. M. J., Paynter, N. P., Steyerberg, E. W., van der Graaf, Y., & Cook, N. R. (2011) · BMJ

Lipoproteins and Cardiovascular HealthStatistical Methods in Clinical Trials

Cited by 177

Socioeconomic Status and Incident Type 2 Diabetes Mellitus: Data from the Women's Health Study

Lee, T. C., Glynn, R. J., Peña, J. M., Paynter, N. P., Conen, D., Ridker, P. M., Pradhan, A. D., Buring, J. E., & Albert, M. A. (2011) · PLoS ONE

Health disparities and outcomesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 116